{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:12:43Z","timestamp":1790075563502,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti-T2 biological therapies have proven to effectively reduce acute exacerbations and daily doses of oral steroids in severe eosinophilic asthma. Despite the remarkable clinical efficacy, there are usually only moderate improvements in airflow limitation, suggesting that other measures of lung function like small airway dysfunction (SAD) might better reflect the clinical response. We aimed to investigate if measures of small airway function would predict and correlate with the clinical response to anti-T2 therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We studied data of patients who were previously included in the German prospective longitudinal All Age Asthma Cohort (ALLIANCE) that recruits asthma patients of all severity grades and inflammatory phenotypes. The selection criteria for this analysis were adult patients with severe eosinophilic asthma under treatment with anti-T2 biological agents. Asthma control was assessed by asthma control test (ACT) and number of severe exacerbations. Small airway function was assessed by the frequency dependence of resistance (FDR, R5-20)) derived from impulse oscillometry (IOS) and the mean forced expiratory flow between 25 and 75% of the forced vital capacity (FEF\n                      <jats:sub>25-75<\/jats:sub>\n                      ). We also studied air trapping (RV and RV\/TLC), blood eosinophils and FeNO. Patients were classified into responders and partial or non-responders. Clinical response was defined as at least 50% reduction in annualized severe exacerbations and daily oral steroid doses accompanied with a minimum increase of 3 points in the ACT score. We used a Receiver Operator Characteristic (ROC) to study the capacity of FDR in predicting clinical response compared to other clinical variable like blood eosinophils. We studied the correlation between FDR measures and clinical response, represented by the ACT score and number of exacerbations, using linear regressions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      20 patients were included (mean age, 59\u2009\u00b1\u20099\u00a0years; 60% female; mean body mass index (BMI), 27.6\u2009\u00b1\u20095.4\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ; mean absolute blood eosinophils, 570\u2009\u00b1\u2009389\/\u00b5l; mean number of severe exacerbations 12\u00a0months prior to initiating the biological therapy, 5.0\u2009\u00b1\u20093; mean predicted FEV1, 76\u2009\u00b1\u200921%; mean predicted FDR, 224\u2009\u00b1\u2009140%; mean daily prednisolone dose, 6.4\u2009\u00b1\u20094.9\u00a0mg; mean ACT score, 15\u2009\u00b1\u20095). Responders had significantly higher baseline FDR compared to partial or non-responders but similar FEV1, FEF\n                      <jats:sub>25\u201375,<\/jats:sub>\n                      RV and RV\/TLC. ROC analysis showed that the combination of FDR and blood eosinophils had the best predictive capacity of the clinical response among all tested clinical markers (FeNO, FEV1, FDR, blood eosinophils) with an AUC of 85% [67\u2013100%], (CI\u2009=\u20090.95, p\u2009=\u20090.01). Linear regressions indicated better associations between improvements in FDR and ACT score (R\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090.42, p\u2009=\u20090.001) than with FEV1 and ACT score (R\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090.25, p\u2009=\u20090.013). Likewise, we observed better associations between improvements in FDR and reduction of exacerbations (R\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090.41, p\u2009=\u20090.001) than with FEV1 (R\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090.20, p\u2009=\u20090.025).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our data suggest that severe SAD may represent a distinct phenotype of eosinophilic asthma that substantially improves under anti-T2 biological therapy. Measures of small airway function might be useful in selecting appropriate patients qualifying for anti-T2 biological therapy in addition to blood eosinophil count.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12931-020-01543-5","type":"journal-article","created":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T08:02:53Z","timestamp":1603267373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Small airway dysfunction as predictor and marker for clinical response to biological therapy in severe eosinophilic asthma: a longitudinal observational study"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3300-1398","authenticated-orcid":false,"given":"Mustafa","family":"Abdo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Watz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Veith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Kirsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Biller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"von Mutius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias V.","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesine","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Waschki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus F.","family":"Rabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Trinkmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bahmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,21]]},"reference":[{"issue":"1","key":"1543_CR1","doi-asserted-by":"publisher","first-page":"1900588","DOI":"10.1183\/13993003.00588-2019","volume":"55","author":"F Holguin","year":"2020","unstructured":"Holguin F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick A, et al. Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline. Eur Respir J. 2020;55(1):1900588.","journal-title":"Eur Respir J."},{"issue":"26","key":"1543_CR2","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","volume":"378","author":"KF Rabe","year":"2018","unstructured":"Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475\u201385.","journal-title":"N Engl J Med"},{"issue":"13","key":"1543_CR3","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198\u2013207.","journal-title":"N Engl J Med"},{"issue":"25","key":"1543_CR4","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","volume":"376","author":"P Nair","year":"2017","unstructured":"Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. Oral Glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448\u201358.","journal-title":"N Engl J Med"},{"issue":"5","key":"1543_CR5","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S2213-2600(19)30049-9","volume":"7","author":"DS Postma","year":"2019","unstructured":"Postma DS, Brightling C, Baldi S, van den Berge M, Fabbri LM, Gagnatelli A, et al. Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. The Lancet Respiratory Medicine. 2019;7(5):402\u201316.","journal-title":"The Lancet Respiratory Medicine"},{"issue":"2","key":"1543_CR6","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jaci.2011.11.017","volume":"129","author":"CS Farah","year":"2012","unstructured":"Farah CS, King GG, Brown NJ, Downie SR, Kermode JA, Hardaker KM, et al. The role of the small airways in the clinical expression of asthma in adults. J Allergy Clin Immunol. 2012;129(2):381\u20137.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1543_CR7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/cea.12257","volume":"44","author":"S Gonem","year":"2014","unstructured":"Gonem S, Natarajan S, Desai D, Corkill S, Singapuri A, Bradding P, et al. Clinical significance of small airway obstruction markers in patients with asthma. Clin Exp Allergy. 2014;44(4):499\u2013507.","journal-title":"Clin Exp Allergy"},{"key":"1543_CR8","doi-asserted-by":"crossref","unstructured":"Bahmer T, Waschki B, Schatz F, Herzmann C, Zabel P, Kirsten A-M et al. Physical activity, airway resistance and small airway dysfunction in severe asthma. Eur Respir J 2017; 49(1).","DOI":"10.1183\/13993003.01827-2016"},{"issue":"1","key":"1543_CR9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12890-018-0705-6","volume":"18","author":"O Fuchs","year":"2018","unstructured":"Fuchs O, Bahmer T, Weckmann M, Dittrich A-M, Schaub B, R\u00f6sler B, et al. The all age asthma cohort (ALLIANCE)\u2014from early beginnings to chronic disease: a longitudinal cohort study. BMC Pulm Med. 2018;18(1):140.","journal-title":"BMC Pulm Med"},{"issue":"2","key":"1543_CR10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343\u201373.","journal-title":"Eur Respir J"},{"issue":"2","key":"1543_CR11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1183\/09031936.05.00034805","volume":"26","author":"MR Miller","year":"2005","unstructured":"Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319\u201338.","journal-title":"Eur Respir J"},{"issue":"3","key":"1543_CR12","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1183\/09031936.05.00035005","volume":"26","author":"J Wanger","year":"2005","unstructured":"Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, et al. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26(3):511\u201322.","journal-title":"Eur Respir J"},{"issue":"6","key":"1543_CR13","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1183\/09031936.03.00089403","volume":"22","author":"E Oostveen","year":"2003","unstructured":"Oostveen E, MacLeod D, Lorino H, Farr\u00e9 R, Hantos Z, Desager K, et al. The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur Respir J. 2003;22(6):1026\u201341.","journal-title":"Eur Respir J"},{"issue":"1","key":"1543_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jaip.2019.06.035","volume":"8","author":"H-Y Chiu","year":"2020","unstructured":"Chiu H-Y, Hsiao Y-H, Su K-C, Lee Y-C, Ko H-K, Perng D-W. Small airway dysfunction by impulse oscillometry in symptomatic patients with preserved pulmonary function. J Allergy Clin Immunol Pract. 2020;8(1):229-235.e3.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"1543_CR15","doi-asserted-by":"publisher","first-page":"e63366","DOI":"10.1371\/journal.pone.0063366","volume":"8","author":"H Schulz","year":"2013","unstructured":"Schulz H, Flexeder C, Behr J, Heier M, Holle R, Huber RM, et al. Reference values of impulse oscillometric lung function indices in adults of advanced age. PLoS ONE. 2013;8(5):e63366.","journal-title":"PLoS ONE"},{"issue":"11","key":"1543_CR16","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","volume":"3","author":"DB Price","year":"2015","unstructured":"Price DB, Rigazio A, Campbell JD, Bleecker ER, Corrigan CJ, Thomas M, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med. 2015;3(11):849\u201358.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"1543_CR17","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","volume":"184","author":"RA Dweik","year":"2011","unstructured":"Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602\u201315.","journal-title":"Am J Respir Crit Care Med"},{"issue":"13","key":"1543_CR18","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","volume":"371","author":"EH Bel","year":"2014","unstructured":"Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189\u201397.","journal-title":"N Engl J Med"},{"issue":"4","key":"1543_CR19","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jaci.2009.06.053","volume":"124","author":"M Schatz","year":"2009","unstructured":"Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol. 2009;124(4):719-23.e1.","journal-title":"J Allergy Clin Immunol"},{"key":"1543_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.rmed.2019.01.016","volume":"148","author":"CS Farah","year":"2019","unstructured":"Farah CS, Badal T, Reed N, Rogers PG, King GG, Thamrin C, et al. Mepolizumab improves small airway function in severe eosinophilic asthma. Respir Med. 2019;148:49\u201353.","journal-title":"Respir Med"},{"key":"1543_CR21","doi-asserted-by":"publisher","first-page":"101899","DOI":"10.1016\/j.pupt.2020.101899","volume":"61","author":"B Sposato","year":"2020","unstructured":"Sposato B, Camiciottoli G, Bacci E, Scalese M, Carpagnano GE, Pelaia C, et al. Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life. Pulm Pharmacol Ther. 2020;61:101899.","journal-title":"Pulm Pharmacol Ther"},{"issue":"4","key":"1543_CR22","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1136\/thoraxjnl-2018-212233","volume":"74","author":"M Lommatzsch","year":"2019","unstructured":"Lommatzsch M, Klein M, Stoll P, Virchow JC. Impact of an increase in the inhaled corticosteroid dose on blood eosinophils in asthma. Thorax. 2019;74(4):417\u20138.","journal-title":"Thorax"},{"issue":"12","key":"1543_CR23","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1164\/rccm.201807-1289LE","volume":"198","author":"HJ Durrington","year":"2018","unstructured":"Durrington HJ, Gioan-Tavernier GO, Maidstone RJ, Krakowiak K, Loudon ASI, Blaikley JF, et al. Time of day affects eosinophil biomarkers in asthma: implications for diagnosis and treatment. Am J Respir Crit Care Med. 2018;198(12):1578\u201381.","journal-title":"Am J Respir Crit Care Med"},{"key":"1543_CR24","unstructured":"Toledo Pons N, van Fm Boven J, Rom\u00e1n-Rodr\u00edguez M, Mill\u00e1n A, W.H. Kocks J, B. Soriano J et al. Eosinophil distribution and description in a population cohort of asthmatic patients. In: Monitoring airway disease. European Respiratory Society; 09282019. PA5031."},{"issue":"1","key":"1543_CR25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S0091-6749(97)70193-3","volume":"100","author":"Q Hamid","year":"1997","unstructured":"Hamid Q, Song Y, Kotsimbos TC, Minshall E, Bai TR, Hegele RG, et al. Inflammation of small airways in asthma. J Allergy Clin Immunol. 1997;100(1):44\u201351.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1543_CR26","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1164\/ajrccm.154.1.8680684","volume":"154","author":"M Synek","year":"1996","unstructured":"Synek M, Beasley R, Frew AJ, Goulding D, Holloway L, Lampe FC, et al. Cellular infiltration of the airways in asthma of varying severity. Am J Respir Crit Care Med. 1996;154(1):224\u201330.","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"1543_CR27","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1164\/rccm.201611-2234OC","volume":"196","author":"EA Kelly","year":"2017","unstructured":"Kelly EA, Esnault S, Liu LY, Evans MD, Johansson MW, Mathur S, et al. Mepolizumab attenuates airway eosinophil numbers, but not their functional phenotype, in asthma. Am J Respir Crit Care Med. 2017;196(11):1385\u201395.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-020-01543-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-020-01543-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-020-01543-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T19:38:13Z","timestamp":1634758693000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-020-01543-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,21]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1543"],"URL":"https:\/\/doi.org\/10.1186\/s12931-020-01543-5","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,21]]},"assertion":[{"value":"29 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study is a part from the prospective longitudinal All Age Asthma Cohort (ALLIANCE). The study was approved by local ethics committee at Medical School Luebeck, Germany, and is registered at clinicaltrials.gov (pediatric arm: NCT02496468; adult arm: NCT02419274).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MA reports no conflict of interest. HW reports personal fees and study honoraria of his employer from AstraZeneca, Boehringer Ingelheim, BerlinChemie, Chiesi, Novartis, GSK, and Sanofi outside the submitted work. VV reports no conflict of interest. AMK reports personal fees and study honoraria of her employer from AstraZeneca, Boehringer Ingelheim, BerlinChemie, Chiesi, Novartis, GSK, and Sanofi outside the submitted work. HB reports no conflict of interest. FP reports no conflict of interest. During the 36\u00a0months prior to publication, EvM Mutius reports to have received personal fees from Pharmaventures, from OM Pharma S. A., from Springer-Verlag GmbH, from Elsevier GmbH and Elsevier Ltd., from Peptinnovate Ltd., from Turun Yliopisto, from Tampereen Yliopisto, from Helsingin Yliopisto, from European Respiratory Society, from Deutsche Pharmazeutische Gesellschaft e. V., from Massachusetts Medical Society, from Chinese University of Hongkong, from European Commission, from B\u00f6hringer Ingelheim International GmbH, from Universiteit Utrecht, Faculteit Diergeneeskunde, from Universit\u00e4t Salzburg, from Georg Thieme Verlag, from Japanese Society of Pediatric Allergy and Clinical Immunology (JSPACI), outside the submitted work; In addition, Dr. von Mutius has a patent LU101064\u2014Barn dust extract for the prevention and treatment of diseases pending, a patent EP2361632: Specific environmental bacteria for the protection from and\/or the treatment of allergic, chronic inflammatory and\/or autoimmune disorders with royalties paid to ProtectImmun GmbH, a patent Publication number EP 1411977: Composition containing bacterial antigens used for the prophylaxis and the treatment of allergic diseases, licensed to ProtectImmun GmbH, a patent Publication number EP1637147: Stable dust extract for allergy protection licensed to ProtectImmun GmbH, and a patent Publication number EP 1964570: Pharmaceutical compound to protect against allergies and inflammatory diseases licensed to ProtectImmun GmbH. MVK reports no conflict of interest. GH reports no conflict of interest. BW reports no conflict of interest. KFR reports personal fees from AstraZeneca, Boehringer Ingelheim, BerlinChemie, Chiesi, Novartis, GSK, and Sanofi outside the submitted work. FT received travel support from Actelion, Berlin Chemie, Boehringer Ingelheim, Chiesi, Novartis, Mundipharma and TEVA as well as speaker or consultation fees from AstraZeneca, Berlin Chemie, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, GlaxoSmithKline, Novartis and Roche, Sanofi aventis, all outside the submitted work. TB reports personal fees from AstraZeneca, Boehringer Ingelheim, BerlinChemie, Chiesi, Novartis, GSK, and Sanofi outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"278"}}